Voglibose (DB04878): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Voglibose is an oral antidiabetic agent belonging to the alpha-glucosidase inhibitor class of drugs. Structurally, it is a valiolamine derivative, classified as a small molecule therapeutic.[1] Its primary mechanism of action is the competitive and reversible inhibition of membrane-bound alpha-glucosidase enzymes located in the brush border of the small intestine. By binding to these enzymes, Voglibose delays the digestion and absorption of complex carbohydrates, thereby effectively mitigating the sharp rise in blood glucose levels that occurs after a meal, a phenomenon known as postprandial hyperglycemia (PPHG).[1]

A defining characteristic of Voglibose is its pharmacokinetic profile, which is marked by minimal systemic absorption. This property confines its therapeutic activity almost exclusively to the gastrointestinal lumen, which in turn dictates its clinical profile. This localized action results in a favorable systemic safety profile, characterized by a negligible risk of hypoglycemia when used as monotherapy and a neutral effect on body weight.[2] Conversely, its adverse effects are predominantly gastrointestinal in nature, including flatulence and diarrhea, which are a direct consequence of its mechanism of action.

The primary clinical application of Voglibose is in the management of Type 2 Diabetes Mellitus (T2DM), where it is used as an adjunct to diet and exercise, either as monotherapy or, more commonly, in combination with other oral hypoglycemic agents or insulin to achieve comprehensive glycemic control.[5] Uniquely, it has also gained regulatory approval in Japan for the prevention of T2DM progression in individuals with impaired glucose tolerance (IGT), a testament to its efficacy in early stages of glycemic dysregulation.[7]

Comparative analyses indicate that Voglibose offers similar glycemic efficacy to other alpha-glucosidase inhibitors, such as acarbose, but with a superior gastrointestinal tolerability profile.[9] While it is a widely prescribed and important therapeutic option in many Asian countries, particularly Japan, India, and China, Voglibose has not received marketing authorization from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This geographical divergence in its regulatory status reflects differing clinical needs, dietary patterns, and the evolution of the global diabetes treatment landscape.[10] Voglibose is thus positioned as a well-tolerated, safe, and effective agent for the targeted management of PPHG, with a significant role in the therapeutic armamentarium of specific global regions.

Section 1: Chemical Profile and Physicochemical Properties

1.1 Nomenclature and Identifiers

The precise chemical identification of a pharmaceutical agent is fundamental to its study and clinical application. The compound is globally recognized by its International Nonproprietary Name (INN) and United States Adopted Name (USAN), Voglibose.[10]

Its unambiguous chemical structure is defined by the International Union of Pure and Applied Chemistry (IUPAC) name: (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol.[1]

In scientific literature and clinical development, Voglibose has also been referred to by several synonyms and research codes. These include the systematic name 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-C-(hydroxymethyl)-D-epi-inositol, the descriptive name N-(1,3-dihydroxy-2-propyl)valiolamine, and the development codes AO-128 (Takeda) and A 71100.[1]

To facilitate cross-referencing across global databases and regulatory systems, Voglibose is assigned a series of unique identifiers. The primary Chemical Abstracts Service (CAS) registry number is 83480-29-9.[1] Its entry in the DrugBank database is

DB04878.[1] Other key identifiers include PubChem Compound ID (CID) 444020, FDA Unique Ingredient Identifier (UNII) S77P977AG8, ChEBI ID CHEBI:32300, ChEMBL ID CHEMBL476960, and KEGG ID D01665.[1]

Under the Anatomical Therapeutic Chemical (ATC) classification system, Voglibose is assigned the code A10BF03. This code places it within the therapeutic group "A10 - Drugs used in diabetes," the pharmacological subgroup "A10B - Blood glucose lowering drugs, excl. insulins," and the chemical subgroup "A10BF - Alpha glucosidase inhibitors," definitively classifying its therapeutic role.[1]

1.2 Molecular Structure and Formula

The molecular formula of Voglibose is , corresponding to a molar mass of 267.278 g·mol⁻¹.[13] Its three-dimensional structure and stereochemistry are critical to its biological activity and are precisely defined by standardized chemical notations:

• SMILES (Simplified Molecular Input Line Entry System): C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO.[1]
• InChI (International Chemical Identifier): InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1.[1]
• InChIKey: FZNCGRZWXLXZSZ-CIQUZCHMSA-N.[1] The InChIKey serves as a unique, hashed digital signature for the molecule, enabling unambiguous database searches.

1.3 Physical and Chemical Properties

In its solid state, Voglibose is described as a white to off-white powder or a colorless crystalline solid.[1] Its physicochemical properties are largely dictated by its molecular structure, which is rich in polar functional groups. The presence of seven hydroxyl (-OH) groups and a secondary amine (-NH-) group makes the molecule highly hydrophilic.

This hydrophilicity is directly responsible for its high solubility in aqueous media. Its water solubility is reported to be 190 g/L.[1] It also exhibits solubility in other polar solvents, such as dimethyl sulfoxide (DMSO) at 2 mg/mL and phosphate-buffered saline (PBS, pH 7.2) at 5 mg/mL.[14] The experimental melting point of the crystalline solid is in the range of

162-163°C.[16] The compound has two pKa values,

12.46 and 7.46, which contribute to its overall neutral character under physiological conditions.[19]

The chemical structure and resulting physicochemical properties of Voglibose are the foundational determinants of its entire pharmacological profile. The high density of polar, hydrogen-bonding functional groups is the direct cause of its high water solubility. According to fundamental principles of pharmacokinetics, highly hydrophilic molecules do not readily diffuse across the lipophilic phospholipid bilayer of cell membranes, such as those of the enterocytes lining the small intestine. This inherent difficulty in passive absorption is the primary reason for the repeated observation that Voglibose undergoes minimal systemic absorption following oral administration.[2] This creates a direct and crucial causal link: the molecular structure dictates the physicochemical property of hydrophilicity, which in turn governs the pharmacokinetic behavior of poor absorption. This ultimately confines the drug's mechanism of action to the gut lumen, a feature that is central to both its therapeutic efficacy and its safety profile.

Identifier / Property	Value	Source(s)
IUPAC Name	(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol	1
CAS Number	83480-29-9	1
DrugBank ID	DB04878	1
ATC Code	A10BF03	1
Molecular Formula		13
Molar Mass	267.278 g·mol⁻¹	13
Physical State	White to off-white powder; Colorless crystalline solid	1
Water Solubility	190 g/L	1
Melting Point	162-163°C	16
pKa Values	12.46, 7.46	19

Section 2: Pharmacology and Mechanism of Action

2.1 Primary Pharmacodynamics: Competitive Alpha-Glucosidase Inhibition

Voglibose is pharmacologically classified as a competitive alpha-glucosidase inhibitor.[2] As a valiolamine derivative, its molecular structure functions as a pseudo-carbohydrate, enabling it to act as a structural mimic of the natural di- and oligosaccharide substrates of digestive enzymes.[1]

The core mechanism of Voglibose involves its high-affinity, competitive, and reversible binding to the active sites of alpha-glucosidase enzymes. These enzymes are membrane-bound proteins located on the brush border of enterocytes, the absorptive cells lining the small intestine.[1] By occupying these active sites, Voglibose physically prevents the natural carbohydrate substrates from binding. This inhibitory action blocks the final step of carbohydrate digestion: the enzymatic hydrolysis of complex carbohydrates (such as oligosaccharides, disaccharides, and trisaccharides) into their constituent, absorbable monosaccharides, primarily glucose.[1]

2.2 Target Enzyme Specificity and Potency

Voglibose exhibits potent and selective inhibitory activity against the key alpha-glucosidases responsible for carbohydrate digestion. Its potency is quantified by the half-maximal inhibitory concentration (), with lower values indicating greater inhibitory power. Studies have determined the following  values against various enzymes:

• Rat sucrase: 0.07 µM [14]
• Rat maltase: 0.11 µM [14]
• Rat isomaltase: 0.16 µM [14]
• Human lysosomal α-glucosidase: 5.6 µM [14]

Another study reported even higher potencies, with  values of 3.9 nM for sucrase and 6.4 nM for maltase.[15] This potent inhibition of enzymes like sucrase, maltase, and isomaltase is central to its therapeutic effect.

A critical aspect of its molecular action is its high degree of selectivity. Voglibose is a potent inhibitor of α-glucosidases but a very weak inhibitor of β-glucosidases. Its  for human β-glucosidase is greater than 1,000 μM, demonstrating a high degree of selectivity.[14] This specificity has direct clinical relevance. Lactase, the enzyme responsible for digesting lactose (milk sugar), is a β-glucosidase. By sparing lactase activity, Voglibose does not interfere with the digestion of dairy products and therefore does not induce the lactose intolerance and associated diarrhea that can be a limiting side effect of less selective agents.[2] This molecular-level design feature is a key contributor to its comparatively favorable tolerability profile.

2.3 Impact on Carbohydrate Metabolism

The direct physiological consequence of alpha-glucosidase inhibition by Voglibose is a significant delay in the rate of carbohydrate digestion and absorption in the upper gastrointestinal tract.[2] Instead of a rapid breakdown and absorption of dietary carbohydrates leading to a sharp post-meal spike in blood glucose, the process is slowed and spread out over a longer period and a larger portion of the intestine.

This action effectively blunts the magnitude of postprandial hyperglycemia (PPHG), which is a primary therapeutic target in diabetes management.[1] The effect of Voglibose is substrate-dependent; it effectively reduces the glycemic impact of complex starches and disaccharides like sucrose and maltose, which require alpha-glucosidase activity for their breakdown. However, it has no effect on blood glucose levels following the direct ingestion of monosaccharides such as glucose, fructose, or lactose, as these do not require this enzymatic step for absorption.[21] This specificity underscores its precise mechanism of action.

2.4 Secondary Effects: GLP-1 Secretion and Other Pathways

In addition to its primary mechanism of direct enzyme inhibition, Voglibose exerts important secondary effects on the gut endocrine system. By delaying carbohydrate digestion, it allows a greater proportion of undigested carbohydrates to reach the distal parts of the small intestine (ileum) and colon. This region is rich in enteroendocrine L-cells, which are stimulated by the presence of nutrients to secrete glucagon-like peptide 1 (GLP-1).[2]

The resulting increase in GLP-1 secretion constitutes a significant secondary antidiabetic mechanism. GLP-1 is an incretin hormone with multiple beneficial effects on glucose homeostasis: it enhances glucose-dependent insulin secretion from pancreatic β-cells, suppresses the secretion of glucagon (a hormone that raises blood glucose) from pancreatic α-cells, slows gastric emptying, and promotes satiety.[2] This GLP-1-mediated pathway may contribute to Voglibose's effects on both postprandial and, to some extent, fasting glucose levels.[2] Furthermore, some evidence suggests that Voglibose may also decrease the activity of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of GLP-1, which would further potentiate and prolong the action of the secreted GLP-1.[15]

This dual mechanism of action—direct enzymatic blockade in the proximal gut and indirect hormonal stimulation in the distal gut—represents a more sophisticated modulation of the gut-pancreas endocrine axis than simple carbohydrate blocking. It allows Voglibose to not only passively slow glucose entry but also to actively engage the body's own physiological mechanisms for improving glucose control.

Emerging research indicates that Voglibose may have other biological activities. Preclinical studies have shown it can modulate hypothalamic expressions of leptin receptors and appetite-related genes, potentially contributing to effects on body weight and food intake.[17] Additionally, a novel line of research has identified Voglibose as a potent antimelanogenic (skin-lightening) agent. This effect is proposed to occur through the inhibition of N-glycan modification of tyrosinase, a key enzyme in melanin synthesis, leading to its degradation and reduced melanin production.[2]

Section 3: Pharmacokinetics (PK): ADME Profile

3.1 Absorption

The defining pharmacokinetic characteristic of Voglibose is its extremely poor and minimal systemic absorption following oral administration.[2] This property is a direct and predictable consequence of its highly hydrophilic chemical structure, which hinders its passage across the lipophilic intestinal epithelium. As a result, Voglibose exerts its therapeutic effect almost entirely locally within the lumen of the gastrointestinal tract.[3]

For many years, this minimal absorption posed a significant bioanalytical challenge, with numerous reports stating that plasma concentrations of the drug were "undetectable" after therapeutic oral doses.[2] This led to a general understanding that a detailed systemic pharmacokinetic profile was not attainable.

3.2 Distribution, Metabolism, and Excretion

Given its negligible absorption, the systemic distribution of Voglibose is minimal. The drug does not significantly enter the bloodstream to be distributed to other tissues.

Similarly, hepatic metabolism is considered negligible.[2] Unlike the related alpha-glucosidase inhibitor acarbose, which undergoes some metabolism by intestinal bacteria [22], Voglibose appears to transit the gastrointestinal tract largely unchanged. To date, no metabolites of Voglibose have been identified in humans.[22]

The primary route of elimination for Voglibose is excretion in the feces as the unchanged parent drug. Consequently, renal excretion is negligible.[2] This pharmacokinetic feature has important clinical implications, particularly for patients with renal impairment.

3.3 Novel Pharmacokinetic Quantification

Despite the historical challenges in detecting Voglibose in plasma, a significant advancement in bioanalytical science has provided the first quantitative pharmacokinetic data for the drug. A recent study employed a novel, highly sensitive, and validated liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method to successfully measure the minute concentrations of Voglibose in the plasma of healthy human volunteers.[19] This work represents a breakthrough, providing the first clear and reportable pharmacokinetic parameters for this poorly absorbed compound.[19]

The key parameters determined in this pivotal study were:

• Maximum Plasma Concentration (): The mean peak plasma concentration was found to be 0.0007 ± 0.0002 ng/mL, which is equivalent to 700 ± 200 femtograms/mL.[19] This extraordinarily low concentration validates previous difficulties in its detection and confirms the minimal extent of its absorption.
• Time to Maximum Concentration (): The time to reach this peak concentration was 1.60 ± 0.33 hours post-administration.[19]
• Plasma Elimination Constant (): The rate constant for elimination from the plasma was reported as 0.105 ± 0.036 hr⁻¹.[19]

This novel quantification provides a more nuanced understanding of Voglibose's disposition, confirming that a tiny fraction of the drug does enter systemic circulation, albeit at levels far below those typically associated with systemic therapeutic effects.

The pharmacokinetic profile of Voglibose presents a notable clinical paradox concerning its use in patients with chronic kidney disease (CKD). The data unequivocally show that renal excretion is negligible, meaning the drug is not cleared by the kidneys.[2] From a purely pharmacokinetic standpoint, this would suggest that the risk of drug accumulation—a primary concern for most medications in patients with CKD—is virtually non-existent for Voglibose. This has led some to conclude that no dose adjustment should be necessary for patients with renal impairment.[28] However, this is starkly contradicted by clinical precautions that advise against its use in patients with CKD, citing risks of edema and heart failure.[5] This discrepancy suggests that the adverse outcomes observed in CKD patients may not be related to systemic drug accumulation but could stem from other effects. For instance, the significant osmotic load of undigested carbohydrates in the gut could cause substantial fluid shifts from the intravascular space into the gastrointestinal lumen, a disturbance that could be particularly poorly tolerated by patients with pre-existing fluid and electrolyte imbalances characteristic of advanced renal disease. This highlights a critical gap between the drug's pharmacokinetic profile and its observed clinical effects in a specific patient population, warranting further investigation.

Pharmacokinetic Parameter	Reported Value (Mean ± SD)	Units	Source(s)
(Maximum Plasma Concentration)	0.0007 ± 0.0002	ng/mL	19
(Time to Maximum Concentration)	1.60 ± 0.33	hours	19
(Plasma Elimination Constant)	0.105 ± 0.036	hr⁻¹	19

Section 4: Clinical Efficacy and Therapeutic Indications

4.1 Primary Indication: Type 2 Diabetes Mellitus (T2DM)

The primary and most widespread indication for Voglibose is the improvement of postprandial hyperglycemia in patients with Type 2 Diabetes Mellitus.[5] It is prescribed as an essential component of a comprehensive diabetes management plan that includes diet and exercise.[5]

Voglibose can be utilized across various stages of T2DM treatment:

• Monotherapy: It is used as a first-line agent when diet and exercise alone are insufficient to achieve glycemic targets, particularly in patients with predominant post-meal glucose excursions.[2]
• Combination Therapy: More frequently, Voglibose is used as an add-on therapy when initial treatment with other oral hypoglycemic agents (OHAs), such as sulfonylureas or metformin, fails to provide adequate glycemic control.[2] Some clinical recommendations suggest its use is most appropriate for patients who have achieved satisfactory fasting glucose levels (e.g., <140 mg/dL) but continue to exhibit significant postprandial hyperglycemia (e.g., >200 mg/dL).[2]
• Add-on to Insulin: Voglibose can be added to insulin regimens in patients with either Type 1 (IDDM) or Type 2 diabetes. In this setting, it helps to improve control of postprandial glucose spikes and can lead to a reduction in total daily insulin requirements and lower glycosylated hemoglobin (HbA1c) levels.[2]

4.2 Prevention of Type 2 Diabetes

A unique and significant indication for Voglibose, particularly in Japan, is for delaying or preventing the progression of Impaired Glucose Tolerance (IGT) to overt T2DM.[6] IGT, often referred to as prediabetes, is a high-risk state for the future development of diabetes.

This indication is supported by a large-scale, randomized clinical trial conducted in a Japanese population (Kawamori et al.), which demonstrated that treatment with Voglibose significantly reduced the hazard ratio for progression to T2DM compared to placebo. The study also found that a significantly higher proportion of subjects in the Voglibose group reverted to normoglycemia.[2] Based on this evidence, Voglibose became the first oral antidiabetic agent to receive regulatory approval in Japan for this preventative indication.[7]

However, it is important to note a point of contention in the global evidence base. A comprehensive Cochrane systematic review, which analyzed data from multiple studies, concluded that there was no conclusive evidence that Voglibose, when compared to diet and exercise or placebo, reduced the incidence of T2DM or improved outcomes such as all-cause mortality or cardiovascular events.[13]

This apparent conflict between a major national trial and a global systematic review may not be a direct contradiction but rather an indication that the efficacy of Voglibose is highly dependent on population-specific characteristics. The mechanism of alpha-glucosidase inhibitors is most impactful in the context of diets rich in complex carbohydrates, as these are the substrates the enzymes act upon. Traditional Japanese and other Asian diets are typically high in carbohydrates like rice and noodles. In such a dietary environment, an agent that specifically targets carbohydrate digestion would be expected to have a more pronounced clinical effect. In contrast, Western diets often have different macronutrient profiles, which may lessen the relative impact of an AGI. Therefore, the discrepancy in findings likely underscores that the therapeutic utility of Voglibose in prediabetes is maximized in populations with specific dietary patterns, which helps explain its regulatory success and clinical prominence in Asia compared to its absence from Western markets.

4.3 Other Investigated and Off-Label Uses

Beyond its core indications in diabetes and prediabetes, Voglibose has been investigated and used in other metabolic disorders where modulation of carbohydrate absorption is beneficial:

• Steroid-induced Diabetes Mellitus: Voglibose is considered a helpful therapeutic option for managing the hyperglycemia that can be induced by glucocorticoid therapy, although extensive clinical data in this specific setting are limited.[2]
• Non-diabetic Hyperinsulinemia: In conditions characterized by excessive insulin secretion independent of glucose levels, Voglibose can be used to prevent reactive hypoglycemic attacks by slowing glucose absorption and blunting the stimulus for insulin release.[2]
• Glycogen Storage Disease (Type Ib): In this rare genetic disorder, Voglibose's ability to inhibit amylase (an α-glucosidase) can help prevent episodes of hypoglycemia by slowing the breakdown of dietary starches.[2]

Section 5: Dosage, Formulations, and Administration

5.1 Available Formulations

Voglibose is marketed in several formulations designed to meet different clinical needs and improve patient adherence.

• Conventional Tablets: The standard formulation is a white, immediate-release tablet, most commonly available in dosage strengths of 0.2 mg and 0.3 mg.[29]
• Orally Disintegrating Tablets (ODT): To enhance convenience and compliance, ODT formulations are also available (e.g., Basen OD, Beglilat OD).[6] These tablets dissolve quickly in the mouth without the need for water, which can be advantageous for patients with difficulty swallowing or for those who need to take medication discreetly. Physicians have noted that this formulation is likely to increase patient compliance.[6]
• Fixed-Dose Combinations (FDCs): Voglibose is frequently co-formulated with other oral antidiabetic agents, most notably metformin. FDCs such as Vogmet and Vocarb-MF are widely available.[10]

The development and clinical adoption of ODT and FDC formulations are not merely matters of convenience; they represent strategic solutions to the primary challenges of AGI therapy. The strict, thrice-daily dosing regimen required for Voglibose can be a barrier to long-term adherence. ODTs directly address this by simplifying the act of administration. More significantly, FDCs address a key therapeutic limitation. Voglibose primarily targets postprandial hyperglycemia, with little effect on fasting plasma glucose (FPG). Metformin, the first-line therapy for T2DM, primarily targets FPG by reducing hepatic glucose production. Combining these two agents in a single tablet creates a complementary and synergistic therapeutic approach, targeting both major defects in T2DM hyperglycemia. This simplifies the treatment regimen, reduces the patient's pill burden, and enhances adherence—all critical factors in the successful long-term management of a chronic disease like diabetes.

5.2 Dosing Regimens

The dosage of Voglibose must be individualized based on the patient's glycemic control and tolerability.

• Standard Adult Dose for T2DM: The usual starting dose is 0.2 mg administered three times daily.[5]
• Dose Titration: If the therapeutic effect is deemed insufficient after a period of 2 to 3 months, the dose may be increased to 0.3 mg three times daily.[29]
• Maximum Dose: The maximum recommended daily dose is generally cited as 0.6 mg, although some sources state that the dose can be increased up to 0.3 mg three times daily (a total of 0.9 mg).[2]
• Dosing in Specific Conditions:
• For non-diabetic hyperinsulinemia and steroid-induced diabetes, a dose of 0.2 mg three times daily is typically recommended.[6]
• For glycogen storage disease, a lower dose of 0.1 mg administered with lunch and dinner may be used to mitigate the risk of hypoglycemia.[6]

5.3 Method of Administration

The timing of Voglibose administration is absolutely critical to its efficacy. Because it works by inhibiting the digestion of carbohydrates from a meal, it must be present in the small intestine at the same time as the food.

• The prescribed dose should be taken orally immediately before each of the three main meals.[6]
• If a patient forgets to take the dose just before the meal, it can be taken during the meal. However, if a considerable amount of time has passed since the meal was consumed, the dose should be skipped. Taking the medication long after a meal is ineffective and may increase the risk of side effects or hypoglycemia if combined with other agents. Patients should be instructed never to take two doses at once to compensate for a missed dose.[29]

Section 6: Safety, Tolerability, and Risk Management

6.1 Adverse Effects Profile

The safety and tolerability profile of Voglibose is a direct and logical consequence of its localized mechanism of action and minimal systemic absorption. Adverse effects are overwhelmingly confined to the gastrointestinal system, while systemic effects like hypoglycemia and weight gain are rare with monotherapy.

• Gastrointestinal Effects (Most Common): The most frequently reported adverse events are a result of the fermentation of undigested carbohydrates by bacteria in the lower intestine. These effects occur in up to 25% of patients and include:
• Flatulence (gas)
• Diarrhea or loose stools
• Abdominal pain, discomfort, or bloating
• Borborygmus (audible bowel sounds)
• Nausea and vomiting .2

These symptoms are typically mild to moderate in intensity and often diminish over time as the patient's body adapts to the medication.2

• Hepatic Effects: Elevations in liver transaminases (GOT, GPT) and other liver enzymes (LDH, γ-GTP, ALP) have been reported, occurring in up to 20% of patients during therapy.[2] While usually transient and asymptomatic, there are rare but serious post-marketing reports of fulminant hepatitis, severe liver dysfunction, and jaundice associated with Voglibose use.[2]
• Metabolic Effects (Hypoglycemia): When used as monotherapy, Voglibose carries a minimal risk of hypoglycemia because its mechanism does not involve stimulating insulin secretion.[4] However, this favorable safety profile changes significantly when it is used in combination therapy. The risk of hypoglycemia is substantially increased when Voglibose is co-administered with insulin or insulin secretagogues, such as sulfonylureas.[32]
• Dermatologic Effects: Skin reactions, including rash and itching, have been reported.[5]
• Rare but Severe Adverse Events:
• Pneumatosis Cystoides Intestinalis: This is a rare condition characterized by the formation of gas-filled cysts in the wall of the intestine. It is a known, albeit infrequent, class effect of alpha-glucosidase inhibitors and should be considered in patients on Voglibose who present with persistent gastrointestinal symptoms.[2]
• Ileus: A rare risk of functional bowel obstruction has been noted.[33]
• Disorders of Consciousness: In patients with severe pre-existing liver cirrhosis, Voglibose has been associated with an exacerbation of hyperammonemia, which can lead to disturbances of consciousness.[30]

6.2 Contraindications

Voglibose is strictly contraindicated in the following patient populations and clinical situations:

• Patients with a known hypersensitivity to Voglibose or any of its components.[28]
• Patients with diabetic ketoacidosis, diabetic coma, or pre-coma.[28]
• Patients with severe infections, severe trauma, or in the immediate pre- or post-operative period, where glycemic control is best managed with insulin.[28]
• Patients with significant chronic intestinal diseases, especially those involving inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), colonic ulceration, or partial/complete gastrointestinal obstruction (or a predisposition to obstruction).[28]
• Patients with conditions that could be exacerbated by increased intestinal gas formation, such as severe hernia, Roemheld syndrome, or intestinal stenosis.[28]

6.3 Warnings and Precautions

Caution should be exercised when prescribing Voglibose to patients with the following conditions:

• A history of abdominal surgery (laparotomy) or ileus.[28]
• Chronic intestinal diseases associated with impaired digestion and absorption.[28]
• Pre-existing hepatic or renal disorders.[5]
• Use during pregnancy and lactation is not recommended unless advised by a physician, as safety has not been established.[28]

Regular monitoring of blood glucose levels is essential for all patients. Periodic monitoring of liver function tests is also recommended due to the potential for hepatic adverse effects.28

6.4 Management of Hypoglycemia

A critical point for patient and clinician education is the management of hypoglycemia should it occur, particularly during combination therapy. Because Voglibose blocks the enzyme (sucrase) that breaks down sucrose (common table sugar) into glucose and fructose, treating hypoglycemia with sucrose-containing products like candy, fruit juice, or non-diet soda will be ineffective, as the absorption of glucose will be delayed.

Therefore, hypoglycemic episodes in patients taking Voglibose must be treated with a source of monosaccharides, such as dextrose (glucose) tablets, glucose gel, or honey. This is a crucial safety consideration that distinguishes the management of hypoglycemia with AGIs from that of other antidiabetic agents.[30]

System Organ Class	Adverse Reaction	Frequency / Incidence	Clinical Notes / Management
Gastrointestinal	Flatulence, Diarrhea, Abdominal Pain, Bloating, Nausea	Common (up to 25%)	A direct result of the drug's mechanism. Often mild and tends to decrease with continued use. Start with a low dose to improve tolerability.
	Pneumatosis Cystoides Intestinalis	Rare	A serious class effect. Requires investigation if GI symptoms are persistent or severe.
	Ileus	Rare	Requires immediate medical attention.
Hepatic	Elevated Liver Enzymes (GOT, GPT, ALP)	Reported (up to 20%)	Usually transient. Regular monitoring of liver function is recommended.
	Fulminant Hepatitis, Jaundice	Very Rare	Serious reactions requiring immediate discontinuation of the drug and medical intervention.
Metabolic	Hypoglycemia	Rare (monotherapy); Common (with insulin/SUs)	Does not stimulate insulin secretion. If it occurs, must be treated with glucose, not sucrose.
Dermatologic	Rash, Itching	Uncommon	Standard management for allergic skin reactions.
Nervous System	Dizziness, Headache	Uncommon	May be related to fluid shifts in some elderly patients.
	Consciousness Disorder	Rare	Reported in patients with severe liver cirrhosis due to exacerbation of hyperammonemia.

Section 7: Drug and Food Interactions

7.1 Pharmacodynamic Interactions

The most clinically significant drug interactions for Voglibose are pharmacodynamic, involving other medications that affect blood glucose levels.

• Other Antidiabetic Agents: Co-administration of Voglibose with insulin or insulin secretagogues (e.g., sulfonylureas) markedly increases the risk of hypoglycemia.[28] The glucose-lowering effects are additive or synergistic. To mitigate this risk, a reduction in the dosage of the concomitant insulin or sulfonylurea may be necessary when initiating Voglibose therapy.[30] The hypoglycemic effects of other agents, such as metformin, may also be enhanced.[28]

7.2 Other Potential Drug Interactions

Several sources list other potential drug-drug interactions, although the clinical significance and underlying mechanisms for some are not well-established.

• Warfarin: General drug interaction databases list a potential interaction with the anticoagulant warfarin.[32] The theoretical basis for this warning is that by altering gastrointestinal motility, Voglibose could potentially affect the absorption of a narrow therapeutic index drug like warfarin. However, this theoretical concern is contradicted by high-quality clinical evidence. A dedicated pharmacokinetic and pharmacodynamic study was conducted to specifically evaluate this interaction. The study found that co-administration of Voglibose did not modify the steady-state pharmacokinetics of warfarin's enantiomers or its pharmacodynamic effect on prothrombin time.[39] This specific, evidence-based finding should supersede the more general, theoretical warning, suggesting that Voglibose and warfarin can be co-administered without dose adjustment.
• Other Medications: Other listed potential interactions include:
• Salicylates (aspirin) [35]
• Thyroid hormones (levothyroxine) [35]
• Anti-HIV medications (zidovudine) [35]
• Asthma medications (theophylline) [35]
• Digestive Enzyme Supplements: Concomitant use of supplements containing digestive enzymes (e.g., amylase, pancreatin) may counteract the effect of Voglibose and reduce its efficacy.[34]

7.3 Food and Alcohol Interactions

• Food: The interaction with food is fundamental to the drug's therapeutic action. Voglibose is only effective when taken with meals, specifically immediately before food consumption, to inhibit the digestion of carbohydrates contained in that meal.[29] Patients should maintain a consistent and balanced diabetic diet, with a regular distribution of carbohydrate intake throughout the day. Consuming excessively high-carbohydrate meals can exacerbate the gastrointestinal side effects of the medication.[28]
• Alcohol: While no direct pharmacokinetic interaction between Voglibose and alcohol is known, alcohol consumption can independently affect blood glucose levels in patients with diabetes, potentially leading to either hypoglycemia or hyperglycemia. It may also worsen glycemic control. Therefore, patients are generally advised to avoid or limit alcohol consumption while on antidiabetic therapy.[34]

Section 8: Comparative Analysis and Place in Therapy

8.1 Comparison with Other Alpha-Glucosidase Inhibitors (AGIs)

Voglibose belongs to a class of drugs that includes two other major agents, Acarbose and Miglitol. While they share a common mechanism, there are critical differences in their pharmacology, pharmacokinetics, and clinical profiles that influence their selection in practice.[13]

• Mechanism of Action: All three are pseudo-carbohydrates that act as competitive inhibitors of brush-border alpha-glucosidases (e.g., sucrase, maltase, glucoamylase).[21] A key difference is that Acarbose also provides significant inhibition of pancreatic alpha-amylase, an enzyme that acts earlier in the digestive process to break down complex starches into oligosaccharides. Voglibose and Miglitol have minimal to no effect on pancreatic alpha-amylase.[22]
• Efficacy: In terms of glycemic control, the available evidence suggests that Voglibose and Acarbose have comparable efficacy. A systematic review and meta-analysis found no significant differences between the two drugs in their ability to reduce HbA1c, fasting blood glucose, or postprandial blood glucose.[9] Another comparative study found that Voglibose produced a greater reduction in HbA1c and PPHG compared to both Miglitol and Acarbose, though this difference did not reach statistical significance.[40]
• Side Effect Profile: This is a major point of differentiation. Multiple studies and reviews consistently report that Voglibose has a superior gastrointestinal tolerability profile compared to Acarbose. The incidence and severity of adverse effects such as flatulence, diarrhea, and abdominal distention are significantly lower with Voglibose.[2] This improved tolerability is a primary reason why Voglibose may be preferred in clinical practice.
• Pharmacokinetics: The pharmacokinetic profiles of the three agents are distinct. Both Voglibose and Acarbose are characterized by very poor systemic absorption. In contrast, Miglitol is almost completely absorbed from the small intestine and is subsequently cleared, unchanged, by the kidneys.[22] This fundamental difference means that Miglitol has the potential for systemic effects and is contraindicated in patients with significant renal impairment due to the risk of accumulation. The negligible absorption of Voglibose and Acarbose makes them theoretically safer in this regard.
• Other Effects: Some evidence suggests that Acarbose may have additional cardiovascular benefits, such as stabilizing carotid plaques and reducing inflammatory markers, which have not been as extensively documented for Voglibose or Miglitol.[22]

8.2 Positioning Among Other Oral Antidiabetic Agents (OHAs)

Voglibose's place in the broader diabetes treatment algorithm is best understood by comparing its profile of efficacy, safety, and side effects against other major classes of oral hypoglycemic agents.

• vs. Metformin (Biguanide): Metformin is the undisputed first-line therapy for T2DM worldwide. It offers superior HbA1c reduction (typically 1.0–1.5%), is weight-neutral or promotes slight weight loss, has a low risk of hypoglycemia, and is the only OHA with robust, long-term evidence of cardiovascular benefit in overweight patients. Voglibose has more modest HbA1c-lowering effects (0.5–1.0%) and lacks proven macrovascular benefits. However, its specific and potent effect on PPHG is superior to that of metformin. They are often used in combination to provide comprehensive glycemic control, targeting both fasting glucose (metformin) and postprandial glucose (Voglibose).[4]
• vs. Sulfonylureas (e.g., Glibenclamide): Sulfonylureas are potent insulin secretagogues that can lower HbA1c by 1.0–2.0%. However, their utility is limited by a high risk of hypoglycemia and a tendency to cause weight gain. Voglibose offers a much safer alternative, with its minimal risk of hypoglycemia and weight-neutral profile, making it a preferable option for elderly patients or those in whom hypoglycemia would be particularly dangerous.[4]
• vs. DPP-4 Inhibitors (e.g., Sitagliptin): Like Voglibose, DPP-4 inhibitors are weight-neutral and have a low risk of hypoglycemia. Direct comparison studies have shown that sitagliptin provides superior HbA1c reduction compared to Voglibose. However, the two drugs may have different pleiotropic effects; one study found Voglibose altered serum fatty acid profiles and increased Δ-5 desaturase activity, while sitagliptin had a greater impact on markers of renal function.[41]
• vs. SGLT2 Inhibitors (e.g., Empagliflozin): SGLT2 inhibitors offer moderate HbA1c reduction, promote weight loss through glycosuria, and, most importantly, have demonstrated significant cardiovascular and renal protective benefits in large-scale outcome trials. This has elevated them to a preferred status for patients with or at high risk for atherosclerotic cardiovascular disease, heart failure, or CKD. Voglibose currently lacks this level of evidence for cardio-renal protection.[4]
• vs. Thiazolidinediones (TZDs, e.g., Pioglitazone): TZDs are potent insulin sensitizers but are associated with significant side effects, including weight gain, fluid retention, edema, and an increased risk of heart failure and bone fractures. While some studies show comparable HbA1c lowering between pioglitazone and Voglibose, pioglitazone had a better effect on fasting glucose and lipid profiles. Voglibose's safety profile is substantially more favorable, as it avoids these systemic adverse events.[4]

In summary, Voglibose does not position itself as a powerful, first-line agent for drastic HbA1c reduction. Instead, its therapeutic niche is that of a highly targeted, safe, and physiologically-oriented modulator of carbohydrate metabolism. Its primary value lies in its precision for controlling PPHG, its outstanding safety profile with respect to hypoglycemia and weight gain, and its synergistic potential in combination therapy. This makes it an ideal choice for individualizing treatment, especially in patients with predominant post-meal hyperglycemia, those at high risk for hypoglycemia, or those in the early stages of glucose intolerance, particularly within populations consuming high-carbohydrate diets. It is a tool of finesse rather than force in the management of T2DM.

Parameter	Voglibose	Acarbose	Miglitol
Primary Enzyme Target(s)	Intestinal α-glucosidases (sucrase, maltase, etc.)	Pancreatic α-amylase & Intestinal α-glucosidases	Intestinal α-glucosidases
Efficacy (HbA1c Reduction)	Moderate (~0.5-1.0%)	Moderate (~0.5-1.0%)	Moderate (~0.5-1.0%)
GI Tolerability	Good; lower incidence of side effects	Fair; higher incidence of side effects	Fair to Poor; significant GI side effects
Systemic Absorption	Minimal / Poor	Minimal / Poor	High / Complete
Primary Excretion Route	Feces (unchanged)	Feces (unchanged/metabolites)	Urine (unchanged)
Use in Renal Impairment	Caution advised (non-PK reasons)	Caution advised	Contraindicated

Table 5: Voglibose vs. Other Major Oral Antidiabetic Agent Classes

Parameter	AGIs (Voglibose)	Biguanides (Metformin)	Sulfonylureas	DPP-4 Inhibitors	SGLT2 Inhibitors
Mechanism of Action	Delays carbohydrate absorption	↓ Hepatic glucose production, ↑ Insulin sensitivity	↑ Insulin secretion	↑ Incretin levels	↑ Urinary glucose excretion
HbA1c Efficacy	Moderate (0.5-1.0%)	High (1.0-1.5%)	High (1.0-2.0%)	Moderate (0.5-0.8%)	Moderate (0.5-1.0%)
Hypoglycemia Risk	Very Low	Very Low	High	Very Low	Very Low
Weight Impact	Neutral	Neutral / Slight Loss	Gain	Neutral	Loss
Cardiovascular Benefit	Neutral / Unproven	Proven Benefit	Neutral / Potential Risk	Neutral	Proven Benefit

Section 9: Regulatory Status and Global Availability

9.1 Global Regulatory Landscape

The regulatory status and market availability of Voglibose show a distinct geographical divide, with widespread approval and use in Asia contrasting sharply with its absence from Western markets.

• Japan: Voglibose was discovered and developed by Takeda Pharmaceutical Company, Japan's largest pharmaceutical firm. It was first launched in the Japanese market in 1994 under the trade name BASEN.[5] It is a widely used antidiabetic agent in Japan and holds the unique regulatory approval for the prevention of T2DM in patients with Impaired Glucose Tolerance (IGT), an indication not granted in most other regions.[7]
• Other Asian Markets: Following its launch in Japan, Voglibose gained approval and has become a cornerstone of diabetes therapy in many other Asian countries. It is extensively marketed in India, where it is manufactured by numerous companies including Ranbaxy (now Sun Pharma) under trade names like Volix.[1] It is also approved and available in China, South Korea, the Philippines, and Thailand, among others.[10]
• United States (FDA): Voglibose is not approved for marketing by the U.S. Food and Drug Administration (FDA). A thorough search of the FDA's databases for approved drugs and New Drug Applications (NDAs) reveals no marketing authorization for Voglibose in the United States.[44] While the drug has been assigned a USAN and an FDA UNII code, indicating it is a recognized chemical substance, it has not undergone the rigorous clinical trial and review process required for approval as a therapeutic agent.[1]
• Europe (EMA): Similarly, Voglibose is not approved for marketing in the European Union. Since 2005, all new medicines for the treatment of diabetes must undergo the centralized approval procedure at the European Medicines Agency (EMA) to be marketed across the EU.[11] Voglibose has not been granted a marketing authorization through this pathway, and there is no European Public Assessment Report (EPAR) for the drug, confirming its non-approved status in the region.[11]

This stark geographical disparity in regulatory approval is not arbitrary. It reflects a confluence of factors including differing regional clinical needs, population-specific dietary habits, and evolving global regulatory standards. As previously discussed, the high-carbohydrate diets common in Asia make PPHG a more prominent clinical challenge and render AGIs a particularly effective intervention, creating a strong clinical and commercial rationale for their use. In contrast, the therapeutic landscape in the U.S. and Europe has been shaped by the introduction of newer classes of drugs, such as DPP-4 inhibitors and SGLT2 inhibitors. These newer agents, which often offer better tolerability or additional systemic benefits like proven cardiovascular protection, may have preempted the market niche for a GI-focused drug like Voglibose. Furthermore, the increasingly stringent requirements for FDA and EMA approval, particularly the expectation for large-scale cardiovascular outcome trials (CVOTs) for all new diabetes drugs, may have presented a significant financial and logistical deterrent for seeking approval for an older compound with a modest effect size and no established macrovascular benefits. This has resulted in two distinct therapeutic paradigms, with AGIs like Voglibose playing a central role in Asian diabetes management while being largely absent from Western clinical practice.

9.2 Brand Names and Manufacturers

Voglibose is marketed globally under a multitude of brand names, both as a single agent and in fixed-dose combinations.

• Originator: Takeda Pharmaceutical Company (Japan).[13]
• Major Manufacturers: In addition to Takeda, major manufacturers include Sun Pharmaceutical Industries (formerly Ranbaxy Laboratories), Glenmark Pharmaceuticals, and numerous other generic manufacturers, particularly in India and Japan.[1]

Brand Name	Active Ingredient(s)	Country/Region of Availability	Manufacturer
Basen	Voglibose	Japan, China, South Korea, Philippines, Thailand	Takeda
Volix	Voglibose	India	Sun Pharma (Ranbaxy)
Vocarb	Voglibose	India	Glenmark
Glybose	Voglibose	India	Strides Arcolab
Posmeal	Voglibose	India	Unichem
Diavog	Voglibose	Turkey	Neutec Inhaler
Voglex	Voglibose	Philippines	Athena
Voglia	Voglibose	South Korea	Hanmi
Vogmet	Voglibose + Metformin	South Korea	CJ Cheiljedang
Vocarb-MF	Voglibose + Metformin	India	Glenmark
Posmeal-Met	Voglibose + Metformin	India	Unichem
Cetapin-V	Voglibose + Metformin	India	Sanofi Aventis

Section 10: Emerging Research and Future Directions

While Voglibose is a well-established drug for diabetes management in certain parts of the world, ongoing research continues to explore novel applications, strategies to enhance its efficacy, and its potential role in an evolving therapeutic landscape.

10.1 Novel Therapeutic Applications: Dermatology

One of the most intriguing areas of emerging research is the repurposing of Voglibose as a topical antimelanogenic agent for the treatment of hyperpigmentation disorders.[2] This novel application is entirely distinct from its role in glucose metabolism.

The proposed mechanism involves the inhibition of α-glucosidase enzymes that are crucial for the post-translational modification of proteins within the cell, a process known as N-linked glycosylation. Tyrosinase, the rate-limiting enzyme in melanin synthesis, requires proper glycosylation for its stability, trafficking, and enzymatic activity. Preclinical studies have demonstrated that Voglibose blocks the correct N-glycan modification of tyrosinase. This interference leads to a dramatic reduction in the functional tyrosinase protein level, thereby inhibiting melanin production.[2] Further investigation has shown that Voglibose modulates several key signaling pathways implicated in melanogenesis, including the PKA/CREB, MAPK, and AKT pathways.[23]

Crucially, preliminary human skin irritation tests have indicated that Voglibose is safe for topical application at effective concentrations, showing no adverse reactions.[23] This discovery represents a potential "second life" for Voglibose, leveraging a well-characterized molecule with a long history of human use and a known safety profile to develop a new therapy for a completely different field. The advantage of drug repurposing is that it can significantly de-risk and accelerate the development process compared to creating a new chemical entity from scratch. This could potentially transform Voglibose from a niche diabetes drug into a widely used dermatological or cosmeceutical ingredient.

10.2 Enhancing Efficacy through Novel Combination Therapy

Research is also exploring novel combination strategies to enhance the antidiabetic efficacy of Voglibose beyond pairing it with standard OHAs. Recognizing that T2DM involves multiple pathophysiological defects, including oxidative stress and chronic inflammation, one study investigated combining Voglibose with the antioxidants ubiquinone (Coenzyme Q10) and tempol.[53]

The results of this preclinical study were promising, showing that the combination of Voglibose with these agents produced superior efficacy compared to Voglibose alone. The combination therapy significantly enhanced insulin secretion, provided greater reductions in blood glucose and HbA1c, and mitigated inflammatory and degenerative tissue changes. This suggests that a multi-target therapeutic strategy—simultaneously addressing postprandial hyperglycemia, oxidative stress, and inflammation—could offer a more comprehensive and effective approach to managing T2DM and its complications.[53]

10.3 Future Research Trajectories

Despite its long history of clinical use, several key research gaps remain for Voglibose, which, if addressed, could clarify and potentially expand its therapeutic role.

• Cardiovascular Outcome Trials (CVOTs): In the modern era of diabetes drug development, the absence of a large-scale, dedicated CVOT is a major limitation for Voglibose. While it is known to improve PPHG, a recognized cardiovascular risk factor, there is no conclusive evidence from large trials to show that it reduces major adverse cardiovascular events (MACE).[4] Conducting such a trial would be essential to elevate its standing in global treatment guidelines and to justify its consideration in patients with high cardiovascular risk.
• Head-to-Head Comparative Trials: While some comparisons exist, more rigorous, head-to-head trials against newer classes of antidiabetic agents, such as DPP-4 inhibitors and SGLT2 inhibitors, are needed. These trials should evaluate not only traditional endpoints like HbA1c but also more nuanced metrics like glycemic variability, patient-reported outcomes (especially concerning GI tolerability), and effects on metabolic markers.[31]
• Novel Drug Delivery Systems: Given that Voglibose's action is entirely localized to the gut, there is potential to optimize its delivery. Advanced formulations using nanotechnology could be explored to create systems that provide a more targeted and sustained release of the drug within the small intestine. Such systems could potentially enhance its efficacy at lower doses, further improve its tolerability profile, and increase patient adherence.[54]

Conclusion

Voglibose is a highly specialized oral antidiabetic agent whose entire clinical profile—its mechanism, efficacy, safety, and therapeutic niche—is fundamentally dictated by its unique pharmacology as a poorly absorbed, luminally-acting alpha-glucosidase inhibitor. Its primary strength lies in its precise and effective control of postprandial hyperglycemia, a critical component of overall glycemic management. This is achieved through a dual mechanism of direct enzymatic inhibition of carbohydrate digestion and indirect stimulation of the beneficial incretin hormone GLP-1.

Its most compelling advantages are found in its safety profile. By avoiding systemic circulation and not stimulating insulin secretion, Voglibose offers a minimal risk of hypoglycemia and a neutral effect on body weight, distinguishing it favorably from older, potent agents like sulfonylureas. Furthermore, comparative evidence indicates a superior gastrointestinal tolerability profile relative to its main class competitor, acarbose, making it a preferable option for many patients.

These attributes have cemented its role as a key therapeutic agent in many Asian countries, where its efficacy is potentially maximized by high-carbohydrate dietary patterns and where it holds a unique approval for the prevention of Type 2 Diabetes in high-risk individuals. Conversely, its absence from the U.S. and European markets reflects a different therapeutic landscape, regulatory environment, and the rise of newer agent classes with proven systemic and cardiovascular benefits.

Ultimately, Voglibose should not be viewed as a universal, first-line agent for all patients with Type 2 Diabetes. Rather, it is a valuable, safe, and effective tool for individualized therapy. It is an ideal choice for patients with predominant postprandial hyperglycemia, for those in whom the avoidance of hypoglycemia and weight gain is a priority, and as a synergistic component of combination therapy. With intriguing emerging research into novel applications such as dermatology, the story of Voglibose continues to evolve, underscoring its enduring, albeit geographically focused, place in the pharmacopeia.

Works cited

1. Voglibose | C10H21NO7 | CID 444020 - PubChem, accessed September 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Voglibose
2. Voglibose: An Alpha Glucosidase Inhibitor - PMC - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3919386/
3. What is the mechanism of Voglibose? - Patsnap Synapse, accessed September 30, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-voglibose
4. International Journal of Research Publication and Reviews ... - ijrpr, accessed September 30, 2025, https://ijrpr.com/uploads/V6ISSUE6/IJRPR47939.pdf
5. Voglibose | Uses | Dosages | Side Effects - Yashoda Hospitals, accessed September 30, 2025, https://www.yashodahospitals.com/medicine-faqs/voglibose/
6. Voglibose: Uses, Side Effects, Dosage and More - CARE Hospitals, accessed September 30, 2025, https://www.carehospitals.com/medicine-detail/voglibose
7. Efficacy of voglibose in type 2 diabetes - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/24798092/
8. Efficacy of voglibose in type 2 diabetes | Request PDF - ResearchGate, accessed September 30, 2025, https://www.researchgate.net/publication/262071655_Efficacy_of_voglibose_in_type_2_diabetes
9. The Efficacy and Safety of Acarbose compared ... - Hilaris Publisher, accessed September 30, 2025, https://www.hilarispublisher.com/open-access/the-efficacy-and-safety-of-acarbose-compared-with-voglibose-in-patients-with-type-2-diabetes-a-systematic-review-and-metaanalysis-2155-9929-1000375.pdf
10. Voglibose (International database) - Drugs.com, accessed September 30, 2025, https://www.drugs.com/international/voglibose.html
11. The European Medicines Agency's approval of new medicines for type 2 diabetes - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6667915/
12. Glubrava | European Medicines Agency (EMA) - Europa.eu, accessed September 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/glubrava
13. Voglibose - Wikipedia, accessed September 30, 2025, https://en.wikipedia.org/wiki/Voglibose
14. Voglibose (AO-128, CAS Number: 83480-29-9) | Cayman Chemical, accessed September 30, 2025, https://www.caymanchem.com/product/14179/voglibose
15. Voglibose | CAS 83480-29-9 | AO 128 | Tocris Bioscience, accessed September 30, 2025, https://www.tocris.com/products/voglibose_3596
16. Voglibose | 83480-29-9 - ChemicalBook, accessed September 30, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4481287.htm
17. Voglibose | CAS 83480-29-9 | SCBT - Santa Cruz Biotechnology, accessed September 30, 2025, https://www.scbt.com/p/voglibose-83480-29-9
18. VOGLIBOSE - precisionFDA, accessed September 30, 2025, https://precision.fda.gov/ginas/app/ui/substances/d8bdb655-e6d8-4a5b-9de9-f89b3f3eb15b
19. Comparative Pharmacokinetic Study of Voglibose A Novel Bio ..., accessed September 30, 2025, https://ijprajournal.com/issue_dcp/Comparative%20Pharmacokinetic%20Study%20of%20Voglibose.pdf
20. Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes - ResearchGate, accessed September 30, 2025, https://www.researchgate.net/publication/234105345_Impact_of_Voglibose_on_the_Pharmacokinetics_of_Dapagliflozin_in_Japanese_Patients_with_Type_2_Diabetes
21. Voglibose – Knowledge and References - Taylor & Francis, accessed September 30, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Voglibose/
22. α-Glucosidase inhibitors and their use in clinical practice - ScienceOpen, accessed September 30, 2025, https://www.scienceopen.com/document_file/217c106c-a59a-4a81-a695-24bb4ba400b4/PubMedCentral/217c106c-a59a-4a81-a695-24bb4ba400b4.pdf
23. Drug Repurposing of Voglibose, a Diabetes Medication for Skin Health - MDPI, accessed September 30, 2025, https://www.mdpi.com/1424-8247/18/2/224
24. Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3687097/
25. Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and - Semantic Scholar, accessed September 30, 2025, https://pdfs.semanticscholar.org/8589/4926905cb81f9e7704d75478df223401929d.pdf
26. Voglibose: An Alpha Glucosidase Inhibitor - JCDR -, accessed September 30, 2025, https://www.jcdr.net/article_fulltext.asp?id=3838
27. Acarbose: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 30, 2025, https://go.drugbank.com/drugs/DB00284
28. Voglibose : Indications, Uses, Dosage, Drugs Interactions, Side effects, accessed September 30, 2025, https://medicaldialogues.in/generics/voglibose-2726312
29. VOGLIBOSE TABLETS 0.3mg "NP" | Kusuri-no-Shiori(Drug Information Sheet), accessed September 30, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=38211
30. VOGLIBOSE TABLETS 0.3mg "YD" | Kusuri-no-Shiori(Drug Information Sheet), accessed September 30, 2025, https://www.rad-ar.or.jp/siori/english/search/result?n=34501
31. Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6581551/
32. Voglibose: Uses, Side Effects, Medicines & Dosage - Truemeds, accessed September 30, 2025, https://www.truemeds.in/drug-salts/voglibose-122
33. What are the side effects of Voglibose? - Patsnap Synapse, accessed September 30, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-voglibose
34. Voglibose: Uses, Side Effects, Dosage and Precautions - Medicover Hospitals, accessed September 30, 2025, https://www.medicoverhospitals.in/medicine/voglibose
35. Voglibose: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed September 30, 2025, https://www.apollopharmacy.in/salt/Voglibose
36. Alpha Glucosidase Inhibitor Drugs - Picmonic, accessed September 30, 2025, https://www.picmonic.com/pathways/physician-assistant/courses/standard/pharmacology-10918/antihyperglycemic-agents-39788/acarbose-precose-and-miglitol-glyset-alpha-glucosidase-inhibitors_2098
37. Galvus | European Medicines Agency (EMA) - Europa.eu, accessed September 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/galvus
38. www.apollopharmacy.in, accessed September 30, 2025, https://www.apollopharmacy.in/salt/Voglibose#:~:text=Drug%2DDrug%20Interactions%3A%20Voglibose%20may,and%20blood%20thinners%20(warfarin).
39. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/9403289/
40. Comparative study of effect of alpha glucosidase inhibitors-miglitol, acarbose and voglibose on postprandial hyperglycemia and glycosylated hemoglobin in type-2 diabetes mellitus - ResearchGate, accessed September 30, 2025, https://www.researchgate.net/publication/289195075_Comparative_study_of_effect_of_alpha_glucosidase_inhibitors-miglitol_acarbose_and_voglibose_on_postprandial_hyperglycemia_and_glycosylated_hemoglobin_in_type-2_diabetes_mellitus
41. Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial, accessed September 30, 2025, https://drc.bmj.com/content/4/1/e000190
42. [PDF] Comparative evaluation of voglibose versus pioglitazone on glycaemic control and lipid profile in patients of type 2 diabetes mellitus on glimepiride and metformin in punjabi population | Semantic Scholar, accessed September 30, 2025, https://www.semanticscholar.org/paper/Comparative-evaluation-of-voglibose-versus-on-and-2-Jindal-Gupta/bbda984841f10ca6fdffa9b5ede5e68020fb7bba
43. Voglibose | MedPath, accessed September 30, 2025, https://trial.medpath.com/drug/0e74a5d91b6b983c/voglibose
44. FDA-Approved Voglibose API Manufacturers & Suppliers - Pharmaoffer.com, accessed September 30, 2025, https://pharmaoffer.com/api-excipient-supplier/glycemic-agents/voglibose/fda
45. 022271Orig1s000 - accessdata.fda.gov, accessed September 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf
46. queryResult - FDA, accessed September 30, 2025, https://www.fda.gov/media/181468/download
47. Reference ID: 3945358 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed September 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205649s004lbl.pdf
48. FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes, accessed September 30, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes
49. Our medicines | Diabetes medications - Novo Nordisk, accessed September 30, 2025, https://www.novonordisk.com/our-products/our-medicines.html
50. European Medicines Agency recommends authorisation of novel treatment for type 2 diabetes - Associazione Medici Endocrinologi, accessed September 30, 2025, https://associazionemediciendocrinologi.it/materiali/news/amenews/amenews_pdf_360371863.pdf
51. Lilly Receives European Marketing Authorization for tirzepatide (Mounjaro®) in KwikPen® Presentation for Two Indications, accessed September 30, 2025, https://www.lilly.com/eu/story/lilly-receives-european-marketing-authorization-for-tirzepatide-mounjaro-r
52. EMA CHMP recommends seven medicines for approval - European Pharmaceutical Review, accessed September 30, 2025, https://www.europeanpharmaceuticalreview.com/news/100643/ema-chmp-recommends-seven-medicines-for-approval/
53. Enhanced Antidiabetic Action through Multi-Target Therapy: A Comparative Study of Voglibose-Based Combinations - ResearchGate, accessed September 30, 2025, https://www.researchgate.net/publication/393500185_Enhanced_Antidiabetic_Action_through_Multi-Target_Therapy_A_Comparative_Study_of_Voglibose-Based_Combinations
54. Advancements in Anti-Diabetic Therapy: A Review of Enhanced Efficacy and Bioavailability of Voglibose Nanoformulations | Bentham Science Publishers, accessed September 30, 2025, https://www.benthamdirect.com/content/journals/cnanom/10.2174/0124681873337339250114074235